Proxy Votes Now

Home › Funds › Live Oak Health Sciences Fund

Live Oak Health Sciences Fund (LOGSX) proxy voting record 2025-2026

Fund family: OAK ASSOCIATES FUNDS · Filed by OAK ASSOCIATES FUNDS (CIK 1050918) · SEC series S000006542

Ticker: LOGSX (C000017877)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 302 with, 14 against, 0 abstentions (not counted as with management). Shareholder proposals: 4 FOR, 10 AGAINST, 0 abstained, by the filing’s own vote-source field.

No item-level comparison with other OAK ASSOCIATES FUNDS funds is possible: no ballot item of this fund was voted by at least three other funds of the family with a clear majority.

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 91.1% of this fund’s 316 such votes could be given a sector; the other 28 (8.9%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care288144.9%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections2260
Say-on-Pay260
Audit-related240
Corporate Governance157
Compensation90
Capital Structure70
Other Social Issues44
Environment or Climate33
Shareholder Rights and Defenses30
Other10

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
McKesson CorporationJuly 30, 2025$5M140
Cardinal Health, Inc.November 5, 2025$5M140
Exelixis, Inc.May 26, 2026$4M140
Amgen Inc.May 19, 2026$3M151
United Therapeutics CorporationJune 26, 2026$3M150
Regeneron Pharmaceuticals, Inc.June 12, 2026$3M70
Cencora, Inc.March 5, 2026$3M130
Johnson & JohnsonApril 23, 2026$2M151

Notable votes against management

MeetingCompanyProposalFundMgmt
May 19, 2026Amgen Inc.Stockholder proposal to require an independent board chairman. Shareholder proposalAgainstFor
April 23, 2026Johnson & JohnsonIndependent Board Chair Shareholder proposalAgainstFor
May 15, 2026Medpace Holdings, Inc.Stockholder proposal regarding giving shareholders an ability to call for a special shareholder meeting, if properly presented at the meeting. Shareholder proposalForAgainst
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
May 13, 2026Vertex Pharmaceuticals IncorporatedShareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalForAgainst
April 22, 2026The Cigna GroupShareholder Proposal - Shareholder Right to Act by Written Consent Shareholder proposalForAgainst
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalForAgainst
May 4, 2026Eli Lilly and CompanyShareholder proposal to prepare an annual lobbying report. Shareholder proposalAgainstFor
May 13, 2026Elevance Health, Inc.Shareholder Proposal Requesting an Independent Study on the Impact of Prohibiting Corporate Contributions to Partisan 527 Tax-Exempt Political Groups. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor

Search this fund’s votes by company

318 ballot items at 25 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Live Oak Health Sciences Fund (LOGSX) voted at 25 shareholder meetings of 25 companies, on 318 ballot items in all. Where management made a recommendation, the fund followed it on 95.6% of the items and voted against it 14 times. Its most frequent area of disagreement was corporate governance (7 of its votes against management). It voted on 14 shareholder proposals.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026. The interactive database shows the same votes company by company, with every other fund that voted.